Today, Boehringer Ingelheim announced that they are partnering with Aural Analytics and VeraSci on an innovative phase III program in cognitive impairment associated with schizophrenia (CIAS) for the investigational treatment Boehringer Ingelheim 425809. The FDA has granted Breakthrough Therapy Designation (BTD) for Boehringer Ingelheim 425809 for the treatment of CIAS.
The CONNEX trial program will incorporate disease specific speech biomarker technology from Aural Analytics that will be seamlessly embedded into VeraSci’s Pathway platform to provide a richer picture of trial participants’ cognition alongside more conventional clinical outcome measures. Additional information about the studies can be found at www.clinicaltrials.gov under the identifiers NCT04846868, NCT04846881, and NCT04860830.
“Interventions to improve patients’ lives are a key driver for our partnership with Boehringer Ingelheim and VeraSci as part of this first-of-a-kind trial program,” said Aural Analytics Co-Founder & CEO Daniel Jones. “Several of the symptoms of schizophrenia are generated by cognitive and emotional processes that can be identified through disruptions in the outward flow of speech. Using innovative speech analytics may help to objectively assess the downstream consequences of these disruptions.”
